drugset / Trial / NCT00268307

Bone Marrow Stem Cell Infusion Following a Heart Attack

NCT00268307 ↗

RandomizedCrossoverQuadruple-blindTreatment

Summary

The goal of this study is to determine the safety of giving a patient's own bone marrow-derived stem cells delivered with a catheter (tube) into the coronary arteries (blood vessels of the heart). Stem cells are simple cells produced by the bone marrow that can develop into many types of cells. It is possible that these cells will decrease the size of damage caused to the heart from a heart attack and increase the pumping efficiency of the heart; which can be decreased due to a heart attack. The stem cells will be taken from bone marrow and then given back into the heart vessels.

Timeline

Start
2005-12
Primary completion
2010-01
Completion
2010-09

Outcome

Missed primary endpoint

paper The improvement in LV ejection fraction at 6 months by cMRI in the cell therapy group was not different than the placebo group. PMID 20826249 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous, Unfractionated Bone Marrow Mononuclear Cells Unknown 1e+08 cells Other